Twist Bioscience Corp (NASDAQ:TWST) COO Patrick Weiss sold 4,089 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $22.29, for a total transaction of $91,143.81. Following the sale, the chief operating officer now directly owns 95,628 shares of the company’s stock, valued at approximately $2,131,548.12. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
TWST stock traded down $1.11 during mid-day trading on Thursday, reaching $21.80. 448,100 shares of the company traded hands, compared to its average volume of 446,487. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.28 and a quick ratio of 5.03. The company has a market capitalization of $761.99 million, a P/E ratio of -5.46 and a beta of 0.71. Twist Bioscience Corp has a 52-week low of $19.64 and a 52-week high of $35.95. The company has a fifty day moving average price of $23.17 and a 200-day moving average price of $25.68.
Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Wednesday, December 11th. The company reported ($0.96) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.84) by ($0.12). The company had revenue of $15.74 million for the quarter, compared to analysts’ expectations of $14.08 million. Twist Bioscience had a negative net margin of 197.98% and a negative return on equity of 73.98%. As a group, analysts forecast that Twist Bioscience Corp will post -3.11 EPS for the current year.
TWST has been the subject of several recent analyst reports. ValuEngine raised shares of Twist Bioscience from a “hold” rating to a “buy” rating in a research report on Friday, December 27th. Zacks Investment Research cut Twist Bioscience from a “hold” rating to a “sell” rating in a research note on Saturday, October 5th.
About Twist Bioscience
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.
Featured Article: Why does a company issue an IPO?
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.